149 related articles for article (PubMed ID: 29155490)
1. Elimination profile of triamcinolone in urine following oral administration.
Chen TT; Tseng YC; Huang TY; Chang-Chien GP; Hsu MC
Drug Test Anal; 2018 May; 10(5):860-864. PubMed ID: 29155490
[TBL] [Abstract][Full Text] [Related]
2. Positive doping results caused by the single-dose local injection of triamcinolone acetonide.
Chang CW; Huang TY; Tseng YC; Chang-Chien GP; Lin SF; Hsu MC
Forensic Sci Int; 2014 Nov; 244():1-6. PubMed ID: 25126738
[TBL] [Abstract][Full Text] [Related]
3. Effect of glucocorticoid administration on the steroid profile.
Coll S; Matabosch X; Garrostas L; Perez-Maña C; Ventura R
Drug Test Anal; 2018 Jun; 10(6):947-955. PubMed ID: 29278450
[TBL] [Abstract][Full Text] [Related]
4. Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations.
Coll S; Monfort N; Matabosch X; Papakonstantinou K; Pérez-Mañá C; Mateus JA; Ventura R
Drug Test Anal; 2020 May; 12(5):629-636. PubMed ID: 31306564
[TBL] [Abstract][Full Text] [Related]
5. Determination of designer doping agent--2-ethylamino-1-phenylbutane--in dietary supplements and excretion study following single oral supplement dose.
Wójtowicz M; Jarek A; Chajewska K; Turek-Lepa E; Kwiatkowska D
J Pharm Biomed Anal; 2015 Nov; 115():523-33. PubMed ID: 26311473
[TBL] [Abstract][Full Text] [Related]
6. Carbon isotope ratio analysis of endogenous glucocorticoid urinary metabolites after cortisone acetate and adrenosterone administration for doping control.
Brooker L; Cawley A; Kazlauskas R; Goebel C; George A
Drug Test Anal; 2012 Dec; 4(12):951-61. PubMed ID: 22987608
[TBL] [Abstract][Full Text] [Related]
7. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
[TBL] [Abstract][Full Text] [Related]
8. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
9. Determination of raloxifene in urine by liquid chromatography-tandem mass spectrometry for doping.
Chen TT; Huang TY; Pan RN; Chang-Chien GP; Hsu MC
J Anal Toxicol; 2013; 37(6):345-50. PubMed ID: 23772059
[TBL] [Abstract][Full Text] [Related]
10. Lomerizine, trimetazidine and bis-(4-fluorophenyl)-methylpiperazine in human urine after oral administration of lomerizine dihydrochloride: analysis by liquid chromatography-high resolution-tandem mass spectrometry.
Okano M; Sato M; Kageyama S
Drug Test Anal; 2018 Nov; 10(11-12):1689-1697. PubMed ID: 30240154
[TBL] [Abstract][Full Text] [Related]
11. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration.
Coll S; Matabosch X; Llorente-Onaindia J; Carbó ML; Pérez-Mañá C; Monfort N; Monfort J; Ventura R
Drug Test Anal; 2019 Nov; 11(11-12):1589-1600. PubMed ID: 31087549
[TBL] [Abstract][Full Text] [Related]
12. Elimination profiles of betamethasone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations.
Coll S; Monfort N; Alechaga É; Matabosch X; Pérez-Mañá C; Ventura R
Drug Test Anal; 2021 Feb; 13(2):348-359. PubMed ID: 32949107
[TBL] [Abstract][Full Text] [Related]
13. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.
Mareck U; Guddat S; Schwenke A; Beuck S; Geyer H; Flenker U; Elers J; Backer V; Thevis M; Schänzer W
Drug Test Anal; 2011; 3(11-12):820-7. PubMed ID: 22081503
[TBL] [Abstract][Full Text] [Related]
14. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
15. Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".
Cawley AT; Hine ER; Trout GJ; George AV; Kazlauskas R
Forensic Sci Int; 2004 Jul; 143(2-3):103-14. PubMed ID: 15240029
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the urinary excretion of prednisolone and metabolites after nasal administration: Relevance to doping control.
Deventer K; Polet M; Van Gansbeke W; Hooghe F; Van Hoecke H; Van Eenoo P
Drug Test Anal; 2021 Nov; 13(11-12):1897-1905. PubMed ID: 34081842
[TBL] [Abstract][Full Text] [Related]
17. Elimination profiles of prednisone and prednisolone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations.
Coll S; Monfort N; Alechaga É; Matabosch X; Pozo OJ; Pérez-Mañá C; Ventura R
Drug Test Anal; 2021 Mar; 13(3):571-582. PubMed ID: 33161623
[TBL] [Abstract][Full Text] [Related]
18. Analysis of tolvaptan and its metabolites in sports drug testing by high-performance liquid chromatography coupled to tandem mass spectrometry.
Rzeppa S; Viet LN
Drug Test Anal; 2016 Oct; 8(10):1090-1094. PubMed ID: 26768215
[TBL] [Abstract][Full Text] [Related]
19. The atypical excretion profile of meldonium: Comparison of urinary detection windows after single- and multiple-dose application in healthy volunteers.
Görgens C; Guddat S; Bosse C; Geyer H; Pop V; Schänzer W; Thevis M
J Pharm Biomed Anal; 2017 May; 138():175-179. PubMed ID: 28213178
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
